Rahway Pathology first in the nation to submit 2019 MIPS data to the CAP’s registry using NovoPath LIS software platform

PRINCETON, N.J., March 4, 2020 /PRNewswire/ — NovoPath, Inc. announces that its client Rahway Pathology, P.A., utilizing NovoPathTM software, was the first practice in the U.S. to upload 2019 Merit-based Incentive Payment System (MIPS) data to the College of American Pathologists (CAP) Pathologists Quality Registry.  The CAP’s registry will transmit this data to the Centers of Medicare and Medicaid Services (CMS) once the CMS submission portal is open this year.

NovoPath’s quality metrics and data export capabilities give users a hassle-free way of automatically collecting and reporting quality data to meet all CMS requirements in a timely manner.

“NovoPath captures reportable MIPS data for Quality Measures and automates the process of tracking cases eligible for MIPS reporting,” said Hina Kharbey, Vice President of Business Strategy for NovoPath. “In addition, NovoPath clients can interface with a registry of their choice for reporting.  We’re very pleased to help Rahway Pathology track, collect, and upload the data to the Pathologists Quality Registry.”

“We are committed to meeting CMS MIPS requirements as this will allow us to continue to provide the high level of quality and service our clients and patients expect,” said Dr. Michael Gistrak, Co-Chairman at Rahway Pathology. 

“The CAP congratulates Rahway Pathology on being the first practice to successfully upload all its 2019 quality performance category data and finish its data entry with the Pathologists Quality Registry,” said CAP President-elect Emily E. Volk, MD, MBA, FCAP, who chairs the Pathologists Quality Registry ad hoc committee. “The partnership between the CAP’s Pathologists Quality Registry, NovoPath, and Rahway Pathology is one that can be emulated by other practices to ensure their pathologists have the best qualified clinical data registry for continuous quality improvement and demonstrating their value in MIPS.”

To experience the benefits of NovoPath firsthand, visit www.NovoPath.com and request a complimentary demonstration.

About NovoPath
NovoPath is an ISO 9001certified U.S.-based Lab Information Systems (LIS) company that serves the Anatomic and Clinical Pathology, Molecular and Genetic Testing, and Clinical Trials markets. We partner with your lab to identify efficiencies, improve workflow and reduce the probability of human error so you can focus on excellent patient care. Built on more than 25 years of industry partnerships, our flexible and reliable workflow and business solutions are engineered to empower your lab to perform at its best. Our clients include national and regional reference labs, university and teaching hospitals, regional and community hospitals, and specialty labs.

Media Contact:
Wally Soufi
732-329-3209
235335@email4pr.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/rahway-pathology-first-in-the-nation-to-submit-2019-mips-data-to-the-caps-registry-using-novopath-lis-software-platform-301016079.html

SOURCE NovoPath, Inc.

Staff

Recent Posts

NervGen Pharma Announces Proposed Amendment to Warrants

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB:…

3 hours ago

MyndTec Inc. Completes Ninth Tranche of Non-Brokered Private Placement

Mississauga, Ontario--(Newsfile Corp. - December 12, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"),…

5 hours ago

Dominari Holdings Announces Change of Record Date and Payment Date for $10 Million Cash Dividend

NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) is pleased to announce…

5 hours ago

ISHI Health Launches Virtual Heart Failure Clinics in California and Arizona

SAN DIEGO, Dec. 12, 2025 /PRNewswire/ -- ISHI Health, an innovator in AI-enabled virtual cardiac…

5 hours ago

Zealthy Review 2026: How Zealthy Compares to FitRx and RoenRx for Weight Loss & GLP-1 Care

LOS ANGELES, CA / ACCESS Newswire / December 12, 2025 / The landscape of weight…

5 hours ago

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

ESTERO, FL / ACCESS Newswire / December 12, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP)…

5 hours ago